Shao Hui Huang1, Wei Xu1, John Waldron1, Lillian Siu1, Xiaowei Shen1, Li Tong1, Jolie Ringash1, Andrew Bayley1, John Kim1, Andrew Hope1, John Cho1, Meredith Giuliani1, Aaron Hansen1, Jonathan Irish1, Ralph Gilbert1, Patrick Gullane1, Bayardo Perez-Ordonez1, Ilan Weinreb1, Fei-Fei Liu1, Brian O'Sullivan2. 1. Shao Hui Huang, Wei Xu, John Waldron, Lillian Siu, Xiaowei Shen, Li Tong, Jolie Ringash, Andrew Bayley, John Kim, Andrew Hope, John Cho, Meredith Giuliani, Aaron Hansen, Jonathan Irish, Ralph Gilbert, Patrick Gullane, Bayardo Perez-Ordonez, Ilan Weinreb, Fei-Fei Liu, and Brian O'Sullivan, Princess Margaret Cancer Centre, University of Toronto; and Fei-Fei Liu and Brian O'Sullivan, Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada. 2. Shao Hui Huang, Wei Xu, John Waldron, Lillian Siu, Xiaowei Shen, Li Tong, Jolie Ringash, Andrew Bayley, John Kim, Andrew Hope, John Cho, Meredith Giuliani, Aaron Hansen, Jonathan Irish, Ralph Gilbert, Patrick Gullane, Bayardo Perez-Ordonez, Ilan Weinreb, Fei-Fei Liu, and Brian O'Sullivan, Princess Margaret Cancer Centre, University of Toronto; and Fei-Fei Liu and Brian O'Sullivan, Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada. Brian.OSullivan@rmp.uhn.on.ca.
Abstract
PURPOSE: To refine stage and prognostic group for human papillomavirus (HPV) -related nonmetastatic (M0) oropharyngeal cancer (OPC). METHODS: All patients with nonmetastatic (M0) p16-confirmed OPC treated with radiotherapy with or without chemotherapy from 2000 to 2010 were included. Overall survival (OS) was compared among TNM stages for patients with HPV-related and HPV-unrelated OPC separately. For HPV-related OPC, recursive partitioning analysis (RPA) derived new RPA stages objectively. Cox regression was used to calculate adjusted hazard ratios (AHRs) to derive AHR stages. The performance of survival prediction of RPA stage and AHR stage was assessed against the current seventh edition TNM stages. Prognostic groups were derived by RPA, combining RPA stage and nonanatomic factors. RESULTS: The cohort comprised 573 patients with HPV-related OPC and 237 patients with HPV-unrelated OPC, with a median follow-up of 5.1 years. Lower 5-year OS with higher TNM stage was evident for patients with HPV-unrelated OPC (stage I, II, III, and IV 5-year OS: 70%, 58%, 50%, and 30%, respectively; P = .004) but not for patients with HPV-related OPC (stage I, II, III, and IV 5-year OS: 88%, 78%, 71%, and 74%, respectively; P = .56). RPA divided HPV-related OPC into RPA-I (T1-3N0-2b), RPA-II (T1-3N2c), and RPA-III (T4 or N3; 5-year OS: 82%, 76%, and 54%, respectively; P < .001). AHR also yielded a valid classification, but RPA stage demonstrated better survival prediction. A further RPA (including RPA stage, age, and smoking pack-years [PYs]) derived the following four valid prognostic groups for survival: group I (T1-3N0-N2c_≤ 20 PY), group II (T1-3N0-N2c_> 20 PY), group III (T4 or N3_age ≤ 70), and group IVA (T4 or N3_age > 70; 5-year OS: 89%, 64%, 57%, and 40%, respectively; P < .001). CONCLUSION: An RPA-based TNM stage grouping (stage I/II/III: T1-3N0-N2b/T1-3N2c/T4 or N3, with M1 as stage IV) is proposed for HPV-related OPC as a result of significantly improved survival prediction compared with the seventh edition TNM, and prognostication is further improved by an RPA-based prognostic grouping within the American Joint Committee on Cancer/Union for International Cancer Control TNM framework for HPV-related OPC.
PURPOSE: To refine stage and prognostic group for human papillomavirus (HPV) -related nonmetastatic (M0) oropharyngeal cancer (OPC). METHODS: All patients with nonmetastatic (M0) p16-confirmed OPC treated with radiotherapy with or without chemotherapy from 2000 to 2010 were included. Overall survival (OS) was compared among TNM stages for patients with HPV-related and HPV-unrelated OPC separately. For HPV-related OPC, recursive partitioning analysis (RPA) derived new RPA stages objectively. Cox regression was used to calculate adjusted hazard ratios (AHRs) to derive AHR stages. The performance of survival prediction of RPA stage and AHR stage was assessed against the current seventh edition TNM stages. Prognostic groups were derived by RPA, combining RPA stage and nonanatomic factors. RESULTS: The cohort comprised 573 patients with HPV-related OPC and 237 patients with HPV-unrelated OPC, with a median follow-up of 5.1 years. Lower 5-year OS with higher TNM stage was evident for patients with HPV-unrelated OPC (stage I, II, III, and IV 5-year OS: 70%, 58%, 50%, and 30%, respectively; P = .004) but not for patients with HPV-related OPC (stage I, II, III, and IV 5-year OS: 88%, 78%, 71%, and 74%, respectively; P = .56). RPA divided HPV-related OPC into RPA-I (T1-3N0-2b), RPA-II (T1-3N2c), and RPA-III (T4 or N3; 5-year OS: 82%, 76%, and 54%, respectively; P < .001). AHR also yielded a valid classification, but RPA stage demonstrated better survival prediction. A further RPA (including RPA stage, age, and smoking pack-years [PYs]) derived the following four valid prognostic groups for survival: group I (T1-3N0-N2c_≤ 20 PY), group II (T1-3N0-N2c_> 20 PY), group III (T4 or N3_age ≤ 70), and group IVA (T4 or N3_age > 70; 5-year OS: 89%, 64%, 57%, and 40%, respectively; P < .001). CONCLUSION: An RPA-based TNM stage grouping (stage I/II/III: T1-3N0-N2b/T1-3N2c/T4 or N3, with M1 as stage IV) is proposed for HPV-related OPC as a result of significantly improved survival prediction compared with the seventh edition TNM, and prognostication is further improved by an RPA-based prognostic grouping within the American Joint Committee on Cancer/Union for International Cancer Control TNM framework for HPV-related OPC.
Authors: Lisa A Peterson; Emily L Bellile; Gregory T Wolf; Shama Virani; Andrew G Shuman; Jeremy M G Taylor; Laura S Rozek Journal: Head Neck Date: 2016-07-19 Impact factor: 3.147
Authors: Huaising C Ko; Shuai Chen; Aaron M Wieland; Menggang Yu; Andrew M Baschnagel; Gregory K Hartig; Paul M Harari; Matthew E Witek Journal: Head Neck Date: 2017-07-24 Impact factor: 3.147
Authors: Mathew Geltzeiler; Marnie Bertolet; William Albergotti; John Gleysteen; Brennan Olson; Michael Persky; Neil Gross; Ryan Li; Peter Andersen; Seungwon Kim; Robert L Ferris; Umamaheswar Duvvuri; Daniel Clayburgh Journal: Oral Oncol Date: 2018-07-22 Impact factor: 5.337
Authors: Douglas R Farquhar; Andrew J Coniglio; Maheer M Masood; Nicholas Lenze; Paul Brennan; Devasena Anantharaman; Behnoush Abedi-Ardekani; Adam M Zanation; Mark C Weissler; Andrew F Olshan; Siddharth Sheth; Trevor G Hackman Journal: Oral Oncol Date: 2020-05-31 Impact factor: 5.337
Authors: Ryan P Goepfert; Jan S Lewin; Martha P Barrow; C David Fuller; Stephen Y Lai; Juhee Song; Brian P Hobbs; G Brandon Gunn; Beth M Beadle; David I Rosenthal; Adam S Garden; Merrill S Kies; Vali A Papadimitrakopoulou; David L Schwartz; Katherine A Hutcheson Journal: Laryngoscope Date: 2016-07-21 Impact factor: 3.325